🐜
|
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
25 auth.
J. I. Fernández-Velasco,
J. Kuhle,
E. Monreal,
V. Meca-Lallana,
J. Meca-Lallana,
G. Izquierdo,
F. Gascón-Giménez,
S. Sainz de la Maza,
P. Walo-Delgado,
A. Maceski,
E. Rodríguez-Martín,
E. Roldán,
N. Villarrubia,
A. Saiz,
Y. Blanco,
...
P. Sánchez,
E. Carreón-Guarnizo,
Y. Aladro,
L. Brieva,
C. Íñiguez,
I. González-Suárez,
L. A. Rodríguez de Antonio,
J. Masjuán,
L. Costa-Frossard,
L. Villar
|
5 |
2021 |
5 🐜
|
🐜
|
Possible Influence of the Route of Treatment Administration on Treatment Adherence in Patients With Multiple Sclerosis.
7 auth.
I. Sánchez Martínez,
María Cerdán Sánchez,
J. López Román,
F. Iniesta Martínez,
E. Carreón-Guarnizo,
J. M. Meca Lallana,
...
Pilar Zafrilla Rentero
|
4 |
2020 |
4 🐜
|
🐜
|
Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis.
13 auth.
Naresh Mutukula,
Zhiqiu Man,
Yuta Takahashi,
F. Iniesta Martínez,
Mariana Morales,
E. Carreón-Guarnizo,
R. Hernández Clares,
D. García-Bernal,
Llanos Martinez Martinez,
J. Lajara,
...
Estrella Nuñez Delicado,
J. M. Meca Lallana,
J. I. Izpisúa Belmonte
|
3 |
2021 |
3 🐜
|
🐢
|
Spasticity in multiple sclerosis and role of glatiramer acetate treatment
J. Meca-Lallana,
R. Hernández-Clares,
E. Carreón-Guarnizo
|
3 |
2015 |
3 🐢
|
🐜
|
Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
10 auth.
Luna Fuentes-Rumí,
R. Hernández-Clares,
E. Carreón-Guarnizo,
G. Valero-López,
F. Iniesta-Martinez,
J. M. Cabrera-Maqueda,
...
A. León-Hernández,
J. Zamarro-Parra,
A. Morales-Ortíz,
J. Meca-Lallana
|
3 |
2020 |
3 🐜
|
🦁
|
[Prevalence of multiple sclerosis in the Region of Murcia].
12 auth.
E. Carreón-Guarnizo,
E. Andreu-Reinon,
M. Cerdán-Sánchez,
R. Carrasco-Torres,
R. Hernández-Clares,
L. Prieto-Valiente,
...
C. Garcia-Escriba,
A. Sola-Roca,
M. E. Martinez-Andreu,
M. Miralles González-Conde,
J. Martín-Fernández,
J. Meca-Lallana
|
2 |
2016 |
2 🦁
|